# Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)

> **NCT00951743** · PHASE2 · UNKNOWN · sponsor: **Rapid Laboratories Inc.** · enrollment: 40 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Adaptavir (monomeric DAPTA)

## Key facts

- **NCT ID:** NCT00951743
- **Lead sponsor:** Rapid Laboratories Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-07
- **Primary completion:** 2010-05
- **Final completion:** 2010-07
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2009-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00951743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00951743, "Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00951743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*